Next Pharmaceutical Products products and prices in Pakistan
Manufacturer Holds a DRAP Drug Manufacturing Licence (DML) for its products. Source: DRAP.
Follow price changes 🔒 Company report (Pharma Pro)Private pharmaceutical manufacturer · Lahore · Pakistan
Lahore-based pharmaceutical manufacturer developing and marketing branded medicines across multiple therapeutic categories.
Next Pharmaceutical Products products in Pakistan
Next Pharmaceutical Products (Pvt.) Ltd has 95 medicine presentations registered in Pakistan under 39 brands, covering 34 generic medicines. Most of its products are in Anti-infectives, Cardiovascular and Pain & musculoskeletal. Its brands with the most registered strengths and packs are Paranext (Paracetamol), Verinoxa (Rivaroxaban), Cefnext (Ceftriaxone) and Ibunext (Ibuprofen). 95 products have an official DRAP price on MedInfoBase. See all 39 brands A to Z
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Next Pharmaceutical Products (Pvt.) Ltd.
- Company type
- Private pharmaceutical manufacturer
- Address
- Plot No. 44 A-B, Sundar Industrial Estate, Lahore, Pakistan
- Website
- nextpharmaceutical.com ↗
- Phone
- +92 42 35297630-2
- info@nextpharco.com
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
See where Next Pharmaceutical Products (Pvt.) Ltd is priced against the market
92 of its products have like-for-like competitors. Pharma Pro shows how many are priced below, near or above the market median, the company's overall price position, and product-by-product examples.
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
🔒 3 more overlapping companies, with shared-generic detail, in Pharma Pro. Unlock
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Glinext | Gliclazide | 80 mg | Tablet | 20's | 084470 | PKR 181.52 | PKR 9.08/tablet | 🔒 Pharma Pro |
| Glinext MR | Gliclazide | 30 mg | Tablet | 30's | 084468 | PKR 408.92 | PKR 13.63/tablet | 🔒 Pharma Pro |
| Glinext MR | Gliclazide | 30 mg | Tablet | 20's | 084468 | PKR 273.27 | PKR 13.66/tablet | 🔒 Pharma Pro |
| Glinext MR | Gliclazide | 60 mg | Tablet | 30's | 084469 | PKR 678.20 | PKR 22.61/tablet | 🔒 Pharma Pro |
| Glinext MR | Gliclazide | 60 mg | Tablet | 20's | 084469 | PKR 452.80 | PKR 22.64/tablet | 🔒 Pharma Pro |
| Nextfor | Metformin | 500 mg | Tablet | 50's | 099169 | PKR 110.34 | PKR 2.21/tablet | 🔒 Pharma Pro |
All 39 Next Pharmaceutical Products brands in Pakistan
- Alacep Ciprofloxacin · 200 mg/100 mL injection, 250 mg tablet, 500 mg tablet
- Amlonext Amlodipine · 10 mg tablet, 5 mg tablet
- Aprichem Aprepitant · 125 mg capsule, 40 mg capsule, 80 mg capsule
- Azithronext Azithromycin · 250 mg capsule, 250 mg tablet, 500 mg tablet
- Candinil-H Clotrimazole + Hydrocortisone · 1 % + 1 % cream
- Cefinext Cefixime · 100 mg/5 mL suspension, 400 mg capsule
- Cefnext Ceftriaxone · 1000 mg injection, 250 mg injection, 500 mg injection
- Cetronext Cetirizine · 10 mg tablet
- Chloronext Hydroxychloroquine · 200 mg tablet
- Clamac Clarithromycin · 250 mg tablet, 500 mg tablet
- Clopinext Clopidogrel · 300 mg tablet, 75 mg tablet
- D-Plasmo 20 Artemether + Lumefantrine · 20 mg + 120 mg tablet
- D-Plasmo DS Artemether + Lumefantrine · 40 mg + 240 mg tablet, 80 mg + 480 mg tablet
- Factosil Lactulose · 3.35 mg/5 mL oral liquid
- Feronext 100/0.35 mg Iron polymaltose complex + Folic acid · 100 mg + 0.35 mg tablet
- Gleetal Escitalopram · 20 mg tablet
- Glinext Gliclazide · 80 mg tablet
- Glinext MR Gliclazide · 30 mg tablet, 60 mg tablet
- HB-More Iron, Elemental Iron · 50 mg/5 mL syrup
- Ibunext Ibuprofen · 100 mg/5 mL suspension, 200 mg tablet, 400 mg tablet
- Linzanext Linezolid · 400 mg tablet, 600 mg tablet
- Loritanext Lopinavir + Ritonavir · 200 mg + 50 mg tablet
- Motizole Metronidazole · 500 mg/100 mL injection
- Moxiflin 400 mg Metronidazole · 400 mg/250 mL infusion
- Nexstan Atorvastatin · 10 mg tablet, 20 mg tablet
- Nextfol Folic acid · 5 mg tablet
- Nextfor Metformin · 500 mg tablet
- Nirober Ribavirin · 200 mg capsule
- Nuskid Cefepime · 500 mg injection
- Omecap Omeprazole · 20 mg capsule, 40 mg capsule
- Oseltanext Oseltamivir · 75 mg capsule
- Paranext Paracetamol · 120 mg suspension, 120 mg/5 mL suspension, 250 mg/5 mL suspension
- Ribane Ribavirin · 400 mg tablet
- Silvanext Silver sulfadiazine · 1% cream
- Velvet-plus Amlodipine + Valsartan + Hydrochlorothiazide · 10 mg + 160 mg + 12.5 mg tablet, 10 mg + 160 mg + 25 mg tablet, 10 mg + 320 mg + 25 mg tablet
- Velvet-plus 10 Amlodipine + Valsartan + Hydrochlorothiazide · 10 mg + 160 mg + 12.5 mg tablet, 10 mg + 160 mg + 25 mg tablet
- Velvet-plus 5 Amlodipine + Valsartan + Hydrochlorothiazide · 5 mg + 160 mg + 12.5 mg tablet, 5 mg + 160 mg + 25 mg tablet
- Verinoxa Rivaroxaban · 10 mg tablet, 15 mg tablet, 20 mg tablet
- Voloxa Levofloxacin · 250 mg tablet, 500 mg tablet
Next Pharmaceutical Products: common questions
How many products does Next Pharmaceutical Products have in Pakistan?
Next Pharmaceutical Products (Pvt.) Ltd has 95 registered medicine presentations in Pakistan, sold under 39 brands and covering 34 generic medicines.
What are the main brands of Next Pharmaceutical Products?
By number of registered strengths and packs, its largest brands are Paranext (Paracetamol), Verinoxa (Rivaroxaban), Cefnext (Ceftriaxone), Ibunext (Ibuprofen) and Velvet-plus (Amlodipine + Valsartan + Hydrochlorothiazide). This is not a sales ranking.
Which therapy areas does Next Pharmaceutical Products cover?
The most products are in Anti-infectives (39), Cardiovascular (13), Pain & musculoskeletal (13), Hematology & thrombosis (10) and Gastrointestinal & hepatology (7).
Where can I see Next Pharmaceutical Products medicine prices?
Open any brand in the list above for its official DRAP price, pack sizes, price history and other brands of the same medicine.
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.